Clinical Trial Update: HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update exploring HAIC with sintilimab and bevacizumab for unresectable intrahepatic cholangiocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intrahepatic Cholangiocarcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• HAIC (hepatic artery infusion chemotherapy)
• Sintilimab (sintilimab)

Snippet

Sponsor: Binkui Li | Conditions: Intrahepatic Cholangiocarcinoma | Phase 2 | Status: UNKNOWN